Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate
Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate
复制标题
DOI：
10.1016/s0264-410x(00)00057-8
复制
发表时间：
2000-06-01
期刊：
影响因子：
5.5
通讯作者：
Power, UF
中科院分区：
文献类型：
--
作者：
Goetsch, L;Plotnicky-Gilquin, H;Power, UF
在不同剂量、给药途径和免疫次数条件下，在 BALB/c 小鼠中评估了 BBG2Na（一种新型重组呼吸道合胞病毒亚单位候选疫苗）的免疫原性和保护功效。单次腹膜内 (i.p.) 2 μg 剂量或两次 0.2 μg 剂量足以诱导 RSV-A 血清抗体升高并消除肺部保护性免疫。第二次免疫后血清抗体滴度显着升高，但第三次则没有。在三种免疫途径中，腹膜内注射（ip）。诱导的 RSV-A 抗体滴度最高，其次是肌内 (i.m) 和皮下 (s.c.) 途径的功效。尽管如此，所有三种途径都产生了类似的灭菌性肺保护作用。相反，仅在腹膜内注射后才观察到上呼吸道保护。疫苗接种，尽管肌肉注射后病毒滴度明显降低。或 s.c.免疫接种。有趣的是，Pepscan 分析表明，腹腔注射中抗体表位的使用率最高。最低的 i.m.分别免疫小鼠。尽管如此，所有途径都会导致抗体对已知的肺保护表位（保护位）产生反应。因此，预防严重的下呼吸道疾病（RSV 疫苗的主要目标，而不是 URT 感染）是剂量依赖性的，但不太可能受到 BBG2Na 给药途径的影响。 (C) 2000 Elsevier Science Ltd. 保留所有权利。
The immunogenicity and protective efficacy of BBG2Na, a novel recombinant respiratory syncytial virus subunit vaccine candidate, was assessed in BALB/c mice under various conditions of dose, administration route and number of immunisations. A single intra-peritoneal (i.p.) dose of 2 mu g, or two doses of 0.2 mu g, were sufficient to induce elevated RSV-A serum antibodies and sterilising lung protective immunity. Serum antibody titres were significantly boosted following second immunisations, but not a third. Of three routes of immunisation, i.p. induced the highest RSV-A antibody titres, followed in efficacy by the intramuscular (i.m.) and subcutaneous (s.c.) routes. Nonetheless, all three routes induced comparable and sterilising lung protection. In contrast, upper respiratory tract protection was observed only after i.p. vaccination, although significant viral titre reductions were evident following i.m. or s.c. immunisations. Interestingly, Pepscan analyses indicated that antibody epitope usage was highest in i.p. and lowest in i.m. immunised mice, respectively. Nonetheless, all routes resulted in antibody responses to known lung protective epitopes (protectopes). Thus, the prevention of serious lower respiratory tract disease, the principle goal of a RSV vaccine, but not URT infection, is dose dependent but unlikely to be influenced by the route of BBG2Na administration. (C) 2000 Elsevier Science Ltd. All rights reserved.